APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis

NASDAQ:APLS • US03753U1060

21.7 USD
-0.35 (-1.59%)
At close: Feb 13, 2026
21.7 USD
0 (0%)
After Hours: 2/13/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

APLS gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 522 industry peers in the Biotechnology industry. APLS has an average financial health and profitability rating. APLS is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make APLS suitable for growth investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year APLS was profitable.
  • APLS had a positive operating cash flow in the past year.
  • APLS had negative earnings in each of the past 5 years.
  • APLS had a negative operating cash flow in each of the past 5 years.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

  • The Return On Assets of APLS (4.25%) is better than 90.63% of its industry peers.
  • APLS has a better Return On Equity (11.21%) than 93.12% of its industry peers.
  • The Return On Invested Capital of APLS (8.15%) is better than 94.07% of its industry peers.
Industry RankSector Rank
ROA 4.25%
ROE 11.21%
ROIC 8.15%
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • APLS's Profit Margin of 4.43% is amongst the best of the industry. APLS outperforms 89.10% of its industry peers.
  • APLS has a better Operating Margin (7.91%) than 90.44% of its industry peers.
  • The Gross Margin of APLS (88.85%) is better than 90.82% of its industry peers.
  • APLS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 7.91%
PM (TTM) 4.43%
GM 88.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so APLS is destroying value.
  • The number of shares outstanding for APLS has been increased compared to 1 year ago.
  • The number of shares outstanding for APLS has been increased compared to 5 years ago.
  • APLS has a better debt/assets ratio than last year.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • APLS has an Altman-Z score of 0.62. This is a bad value and indicates that APLS is not financially healthy and even has some risk of bankruptcy.
  • APLS's Altman-Z score of 0.62 is fine compared to the rest of the industry. APLS outperforms 63.29% of its industry peers.
  • The Debt to FCF ratio of APLS is 5.78, which is a neutral value as it means it would take APLS, 5.78 years of fcf income to pay off all of its debts.
  • APLS has a Debt to FCF ratio of 5.78. This is amongst the best in the industry. APLS outperforms 91.78% of its industry peers.
  • APLS has a Debt/Equity ratio of 0.90. This is a neutral value indicating APLS is somewhat dependend on debt financing.
  • The Debt to Equity ratio of APLS (0.90) is worse than 73.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.78
Altman-Z 0.62
ROIC/WACC0.67
WACC12.2%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

  • APLS has a Current Ratio of 3.54. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.54, APLS perfoms like the industry average, outperforming 42.06% of the companies in the same industry.
  • A Quick Ratio of 3.10 indicates that APLS has no problem at all paying its short term obligations.
  • APLS's Quick ratio of 3.10 is on the low side compared to the rest of the industry. APLS is outperformed by 60.61% of its industry peers.
Industry RankSector Rank
Current Ratio 3.54
Quick Ratio 3.1
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • APLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.40%, which is quite impressive.
  • The Revenue has grown by 42.11% in the past year. This is a very strong growth!
  • The Revenue has been growing by 127.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.32% on average over the next years. This is a very strong growth
  • APLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.82% yearly.
EPS Next Y115.15%
EPS Next 2Y9.88%
EPS Next 3Y22.54%
EPS Next 5Y25.32%
Revenue Next Year31.16%
Revenue Next 2Y6.29%
Revenue Next 3Y9.92%
Revenue Next 5Y12.82%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 70.00, APLS can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, APLS is valued cheaper than 89.87% of the companies in the same industry.
  • APLS is valuated expensively when we compare the Price/Earnings ratio to 26.68, which is the current average of the S&P500 Index.
  • APLS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 70
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • 92.16% of the companies in the same industry are more expensive than APLS, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, APLS is valued cheaply inside the industry as 93.12% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 34.92
EV/EBITDA 33.15
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • APLS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as APLS's earnings are expected to grow with 22.54% in the coming years.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y9.88%
EPS Next 3Y22.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • APLS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (2/13/2026, 8:00:00 PM)

After market: 21.7 0 (0%)

21.7

-0.35 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)02-24
Inst Owners101.94%
Inst Owner Change-95.77%
Ins Owners3.7%
Ins Owner Change1.56%
Market Cap2.75B
Revenue(TTM)1.02B
Net Income(TTM)44.99M
Analysts79.29
Price Target34.83 (60.51%)
Short Float %16.99%
Short Ratio6.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.57%
Min EPS beat(2)31.03%
Max EPS beat(2)38.1%
EPS beat(4)3
Avg EPS beat(4)-1.49%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-4.2%
EPS beat(12)7
Avg EPS beat(12)-3.46%
EPS beat(16)7
Avg EPS beat(16)-4.53%
Revenue beat(2)1
Avg Revenue beat(2)1.69%
Min Revenue beat(2)-7.17%
Max Revenue beat(2)10.55%
Revenue beat(4)2
Avg Revenue beat(4)-1.99%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.73%
Revenue beat(12)7
Avg Revenue beat(12)7.96%
Revenue beat(16)10
Avg Revenue beat(16)42.21%
PT rev (1m)-3.87%
PT rev (3m)-10%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-11.59%
EPS NY rev (1m)-10.52%
EPS NY rev (3m)1000.08%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-2.52%
Revenue NY rev (1m)1.89%
Revenue NY rev (3m)4.72%
Valuation
Industry RankSector Rank
PE 70
Fwd PE N/A
P/S 2.7
P/FCF 34.92
P/OCF 34.82
P/B 6.84
P/tB 6.84
EV/EBITDA 33.15
EPS(TTM)0.31
EY1.43%
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)0.62
FCFY2.86%
OCF(TTM)0.62
OCFY2.87%
SpS8.03
BVpS3.17
TBVpS3.17
PEG (NY)0.61
PEG (5Y)N/A
Graham Number4.7
Profitability
Industry RankSector Rank
ROA 4.25%
ROE 11.21%
ROCE 10.32%
ROIC 8.15%
ROICexc 21.17%
ROICexgc 21.17%
OM 7.91%
PM (TTM) 4.43%
GM 88.85%
FCFM 7.74%
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score7
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.78
Debt/EBITDA 4.4
Cap/Depr 13.41%
Cap/Sales 0.02%
Interest Coverage 1.92
Cash Conversion 96.08%
Profit Quality 174.81%
Current Ratio 3.54
Quick Ratio 3.1
Altman-Z 0.62
F-Score7
WACC12.2%
ROIC/WACC0.67
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
EPS Next Y115.15%
EPS Next 2Y9.88%
EPS Next 3Y22.54%
EPS Next 5Y25.32%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
Revenue Next Year31.16%
Revenue Next 2Y6.29%
Revenue Next 3Y9.92%
Revenue Next 5Y12.82%
EBIT growth 1Y136%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.64%
EBIT Next 3Y35.93%
EBIT Next 5Y29.71%
FCF growth 1Y112.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.37%
OCF growth 3YN/A
OCF growth 5YN/A

APELLIS PHARMACEUTICALS INC / APLS FAQ

Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to APLS.


What is the valuation status of APELLIS PHARMACEUTICALS INC (APLS) stock?

ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.


What is the profitability of APLS stock?

APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for APLS stock?

The Earnings per Share (EPS) of APELLIS PHARMACEUTICALS INC (APLS) is expected to grow by 115.15% in the next year.